CHICAGO--(BUSINESS WIRE)--The research group led by Dr. Koji Hasegawa, Director of the Translational Research Division at the National Hospital Organization Kyoto Medical Center and Dr. Tatsuya Morimoto, Professor at the Molecular Medicine School of Pharmaceutical Sciences, University of Shizuoka, announced today based on the recent human clinical trials, that Theracurmin™ has continuously shown positive impact on human diastolic functions. Theracurmin™ is a patented absorption-enhanced form of curcumin, developed by Theravalues Corporation, a Japanese bio-venture.
